Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

90WORKS, INC.

UEI: TNQ8MSCB2R67CAGE: 944X3

90WORKS, INC. is a federal contractor, registered under UEI TNQ8MSCB2R67 and CAGE code 944X3. It has been awarded $26,803,834 across 21 federal contracts. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Veterans Affairs, Department Of Housing And Urban Development, and Department Of Health And Human Services (hhs).

Contact Information

Registration and classification details

Registration

UEI Code

TNQ8MSCB2R67

CAGE Code

944X3

Entity Structure

Corporate Entity (Tax Exempt)

Established

N/A

Business Classifications

A8

NAICS Codes

813410Civic and Social Organizations(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

90WORKS, INC. operates as a specialized government services contractor based in Pensacola, Florida, with a primary focus on nonprofit and charitable organization support under NAICS 813410. While award history is not available to infer specific project deliverables, the company’s classification sugg...

90WORKS, INC. operates as a specialized government services contractor based in Pensacola, Florida, with a primary focus on nonprofit and charitable organization support under NAICS 813410. While award history is not available to infer specific project deliverables, the company’s classification suggests core capabilities in administrative, operational, and programmatic support services for mission-driven entities engaged in federal or state-funded initiatives. This includes grant management, compliance oversight, stakeholder coordination, and organizational capacity building—services critical to sustaining nonprofit operations within the public sector ecosystem. The firm’s technical expertise likely centers on workflow automation, data reporting standards, and regulatory alignment for entities receiving federal funding, though no specific systems, platforms, or certifications are indicated in available records. No agency relationships can be identified due to insufficient award data, and no patterns of engagement with federal departments or independent agencies are discernible from the provided information. Similarly, while NAICS 813410 defines the company’s primary market segment—support for charitable, civic, professional, and similar organizations—there is no evidence of vertical specialization within education, health advocacy, environmental services, or other subsectors. 90WORKS, INC. is structured as an 8H entity, indicating it is a small business owned and controlled by individuals, though it holds no recognized government certifications such as 8(a), HUBZone, or WOSB. Its geographic footprint is localized to Pensacola, Florida, with no indication of multi-state or nationwide operational presence. The company positions itself within the broader nonprofit support services market, serving as a contractor for organizations requiring administrative infrastructure and compliance assistance, though its exact role and scale of operations remain undefined by available contract data.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Department Of Veterans Affairs$25.1M93.8%
Department Of Housing And Urban Development$899.1K3.4%
Department Of Health And Human Services (hhs)$760.4K2.8%
Awards by NAICS
Export
- Unknown NAICS$26.8M100%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in 90WORKS, INC.'s top NAICS codes and agencies

NAICS: 811210
New
Federal
INTENT TO SOLE SOURCE - ABBOTT LABORATORIES
Solicitation # 36C26326P0627
The Department of Veterans Affairs, through its Network Contracting Office 23, intends to award a sole source, firm-fixed price contract to Abbott Laboratories Inc for the service, maintenance, and software support of the EnSite X system. This action is justified under 41 U.S.C. 3304(a)(1) and FAR 13.106-1(b), as the EnSite X system’s service plan is proprietary and no other third-party vendor is authorized to install or service the equipment. The requirement is classified under NAICS code 811210 and product service code J065, and the place of performance is identified as Minneapolis, Minnesota. Although this notice is not a solicitation and does not obligate the government to award a contract, it serves to inform the public of the anticipated sole source award and invites other responsible sources to demonstrate their capability to meet the requirement. Interested vendors may submit capability statements, proposals, or quotations to joseph.bloomer@va.gov no later than seven calendar days after the notice’s publication date of August 6, 2026, with a response deadline of August 16, 2026. The government will evaluate all submissions solely to determine whether the requirement can be met through competitive means, but retains full discretion to proceed with the sole source award regardless of responses received. The contracting officer, Joey Bloomer, may be contacted for further information. No set-aside provisions apply to this action, and the procurement is not open to competitive bidding unless compelling evidence is presented that alternative capable sources exist.
Department Of Veterans Affairs

POSTED

4 days ago

DEADLINE

in 7 days
View Details
NAICS: 513210
New
Federal
Notice of Sole Source: GastroPlus PBPK and PBBM modeling platform subscription
Solicitation # 7571TE26Q00153
The U.S. Food and Drug Administration, through the Department of Health and Human Services, intends to sole-source a firm fixed-price contract to Simulations Plus Inc. for twenty GastroPlus and five DDDPlus software licenses, used for physiologically based pharmacokinetic and physiologically based biopharmaceutics modeling in support of generic drug research. The contract spans a base year from September 1, 2026, to August 31, 2027, with up to three one-year option periods extending through August 31, 2030. Performance will occur at the FDA’s White Oak campus in Silver Spring, Maryland. The acquisition is conducted under RFO 12, allowing for non-competitive procurement of commercial products, and no set-aside applies. Responses are due by August 14, 2026, and any interested party may submit a capability statement to demonstrate their ability to supply the exact software licenses as the original equipment manufacturer or authorized reseller, which the government will review solely to determine whether competitive procurement is warranted. The contract requires the vendor to provide standard individual licenses, with no auto-renewals permitted unless explicitly authorized. Acceptance of deliverables will be conducted by the Contracting Officer’s Representative within 30 working days of delivery, verifying software functionality, compatibility with FDA systems, and compliance with technical requirements. Invoicing must be submitted electronically through the Treasury’s Invoice Processing Platform, and all invoices must include detailed supporting documentation for labor, materials, and costs. The government retains the right to reject nonconforming deliveries and will not pay for services that fail to meet agreed standards. Clauses from the FAR and HHSAR govern payment, representation, whistleblower rights, anti-lobbying, accessibility, and dispute resolution, with federal regulations taking precedence over any vendor terms. The Contracting Officer and Contract Specialist are the primary points of contact, and all vendors must be actively registered in SAM at the time of submission.
Department Of Health And Human Services

POSTED

6 days ago

DEADLINE

in 5 days
View Details
NAICS: 339112
New
Federal
Notice of Intent for Sole Source Award
Solicitation # 36C770AP270038
The Department of Veterans Affairs, through its Network Contracting Office 15, intends to award a sole source contract to Medline Industries LLC for the continued provision of medical and surgical supplies under contract 36C77021D0010, with a proposed start date of October 1, 2026, and a possible six-month extension. This action is taken under FAR 6.103-1 to ensure uninterrupted service to Veterans while the follow-on Request for Proposal is developed for release in the first quarter of Fiscal Year 2027. The contract will be a Firm Fixed-Price agreement for one year, with an option to extend for an additional six months, and requires the vendor to process approximately 44,000 prescriptions daily, ensuring stock fulfillment within 48 hours. The vendor must integrate with the VA’s Health Level 7 system, certified by the VA Office of Information Technology, and comply with all applicable federal, state, and local regulations including those from the FDA, DEA, EPA, and postal and shipping authorities, while maintaining required certifications. No alternative vendors currently possess the ability to meet the VA’s prescription fulfillment requirements without significant delays or operational disruption, making Medline’s continued involvement essential to maintaining timely and reliable delivery of critical supplies to Veterans. While this notice is not a solicitation for competitive bids, responsible sources may submit a capability statement by August 11, 2026, to Phillip Reuwer at phillip.reuwer@va.gov, demonstrating their capacity to meet the same fulfillment timelines and Health Level 7 integration requirements as the current contractor. All submissions must include current VA-approved certification for system connectivity and the ability to handle the volume and speed of prescription processing outlined in the contract. The place of performance is Leavenworth, Kansas, and the NAICS code for this procurement is 339112.
Department Of Veterans Affairs

POSTED

6 days ago

DEADLINE

in 1 day
View Details
NAICS: 339112
New
Federal
Notice of Intent to Award a Sole Source Procurement
Solicitation # 36C77026AP0200
The Department of Veterans Affairs, Network Contracting Office 15, intends to award a sole source contract to McKesson Medical Government Solutions LLC for the continued provision of medical and surgical supplies under a Firm Fixed-Price agreement with a one-year base period and a six-month option, effective October 1, 2026. This action is justified under FAR 6.103-1 due to the unique capability of the current vendor to operate within the VA’s Health Level 7 system, process approximately 3,600 prescriptions daily, and ensure stock fulfillment within 48 hours, capabilities that no other contractor can replicate without substantial implementation delays that would disrupt critical supply chains for Veterans. The contract requires strict compliance with all applicable federal, state, and local regulations including FDA, DEA, EPA, and postal standards, along with ongoing maintenance of required certifications. This interim procurement is designed to maintain uninterrupted service while the follow-on competitive procurement is prepared for release in the first quarter of FY2027. Although this notice does not solicit competitive bids, responsible sources may submit capability statements by August 11, 2026, to demonstrate their ability to meet the same performance standards, including real-time integration with the VA-approved Health Level 7 system and adherence to the 48-hour fulfillment timeline. All submissions must be sent to Phillip Reuwer at the designated VA email address and must include verifiable proof of existing system certification and operational capacity. The place of performance is Leavenworth, Kansas, and the solicitation number is 36C77026AP0200 under NAICS code 339112.
Department Of Veterans Affairs

POSTED

6 days ago

DEADLINE

in 1 day
View Details
NAICS: 339112
New
Federal
Notice of Intent to Sole Source
Solicitation # 36C25626AP4065
The Department of Veterans Affairs, Network Contracting Office 16, intends to award a sole source firm-fixed-price contract to Foresight Imaging LLC for the replacement of the TIMS 2000 SP medical cart used by Speech and Pathology at the Southeast Louisiana Veterans Health Care System in New Orleans, Louisiana. The TIMS 2000 system is essential for capturing dynamic imaging during swallow diagnostics and therapeutic procedures, and Foresight Imaging LLC is the exclusive manufacturer and authorized distributor for both the equipment and its trade-in program, leaving no other source capable of meeting the agency’s requirements. This action is justified under FAR 6.302-1, as no alternative products or services can satisfy the specific operational needs of the facility. The North American Industry Classification System code is 339112, with a Small Business Administration size standard of 1,000 employees, and the product code is 6516 for Medical and Surgical Instruments, Equipment and Supplies. The contract will be performed at 2400 Canal Street, New Orleans, LA 70119. This notice is not a solicitation, nor does it invite competitive proposals or quotes; responses are limited to capability statements from interested parties who wish to demonstrate that competition would be advantageous to the government. All such submissions must be received by August 10, 2026, at 10:00 AM CST, and will be evaluated solely to determine whether competitive procurement should proceed. The Government retains full discretion to proceed with the sole source award or initiate competition based on responses received. No telephone inquiries will be accepted, and no award will be made based on unsolicited offers. The sole point of contact for this action is Contracting Officer Rachel Babin, reachable via email at rachel.babin@va.gov. The solicitation number is 36C25626AP4065, published on August 3, 2026, with a formal response deadline of August 10, 2026, at 3:00 PM CST.
Department Of Veterans Affairs

POSTED

7 days ago

DEADLINE

in about 8 hours
View Details
NAICS: 541715
New
Federal
Antioxidant Therapy for Smith-Lemli-Opitz Syndrone
Solicitation # NICHD-08610
The contract pertains to the development and implementation of antioxidant therapy for Smith-Lemli-Opitz Syndrome, a rare genetic disorder characterized by multiple congenital anomalies and metabolic dysfunction. The solicitation, issued under NICHD-08610 by the Department of Health and Human Services through its National Institutes of Health, invites proposals aimed at advancing targeted antioxidant interventions to mitigate the pathological effects of the condition. The opportunity was posted on August 3, 2026, with responses due by August 18, 2026, at 2:00 PM Eastern Time. The work is expected to be performed in Bethesda, Maryland, consistent with the research infrastructure of the NIH campus. All proposals must be submitted through the SAM.gov portal and should address scientific rigor, feasibility, and potential clinical impact. The primary point of contact for inquiries is Niamh Cawley, with Chung Huang as the secondary contact, both reachable via NIH email addresses. The contracting activity falls under the Department of Health and Human Services with no set-aside provisions specified, and no NAICS code is assigned, indicating flexibility in contractor categorization. Interested parties should ensure adherence to deadlines and submission requirements outlined on the official UI link linked in the posting.
Department Of Health And Human Services

POSTED

7 days ago

DEADLINE

in 8 days
View Details
NAICS: 562111
Federal
Notice of Intent / Sole Source Solid Waste
Solicitation # 75H71026Q00223
The Navajo Area Indian Health Service, Shiprock Service Unit, intends to award a sole-source, firm-fixed-price contract to Navajo Sanitation for solid waste collection services at the Dzilth-Na-O-Dith-Hle Health Center in Bloomfield, New Mexico, with performance beginning September 1, 2026, and ending August 31, 2027. The procurement is justified under unusual and compelling urgency due to the contractor’s unique, uninterrupted history of providing essential waste management services at the facility, ensuring continuity of operations critical to patient care. The North American Industry Classification System code is 562111, with a small business size standard of $47 million in annual revenue. No competitive solicitation will be issued unless a respondent submits clear and convincing evidence that competition would benefit the government. Responses must be submitted in writing as a capability statement by August 17, 2026, at 10:00 a.m. MST, and must not include proprietary, classified, confidential, or sensitive information. The government is not obligated to respond to or acknowledge submissions, and failure to receive affirmative responses will result in contract award without further notice. All information provided may be used in future solicitations if competition is pursued, and any resulting solicitation will be publicly announced on SAM.gov. The point of contact for inquiries is Ken Parrish, Purchasing Agent, reachable at ken.parrish@ihs.gov.
Department Of Health And Human Services

POSTED

11 days ago

DEADLINE

in 8 days
View Details
NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.
Department of Health and Human Services

POSTED

2 months ago

DEADLINE

in 8 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
This funding opportunity supports U.S. small businesses in advancing early-stage research and development toward commercialization through the SBIR program, administered by the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Eligible small businesses must be U.S.-owned and operated with fewer than 500 employees and are expected to lead the majority of the technical effort, with the principal investigator primarily employed by the business. The program offers Phase I grants to establish technical feasibility, Phase II grants to advance development toward market readiness, and two special pathways: Direct to Phase II for projects with prior proof of concept but no prior Phase I award, and Fast-Track for combined Phase I and Phase II submissions reviewed concurrently to accelerate progress. All awards are granted to the small business, and commercialization must be pursued using non-SBIR funds after Phase II. The scientific scope must align with the missions of participating NIH, CDC, or FDA components, focusing on health improvement and public health innovation, with applicants encouraged to consult specific institute priorities and the White House’s Make Our Children Healthy Again Strategy. While clinical trials are permitted, they are explicitly excluded if the application aligns solely with certain NIH institutes or all FDA centers, making alignment critical for responsiveness. Applications must be submitted through the designated portal by the deadline, and while applicants are not required to specify an awarding component during submission, consultation with program staff beforehand is strongly advised to ensure proper alignment. The solicitation operates under a complete small business set-aside mandate and is open to new applications only, with no renewals accepted for Direct to Phase II submissions.
Department of Health and Human Services

POSTED

2 months ago

DEADLINE

in 8 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The Commercialization Readiness Pilot (CRP) program, issued under PAR-27-098, provides late-stage research and development funding and technical assistance to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award or a Phase IIB Strategic Breakthrough award. This initiative is designed to bridge the gap between Phase II completion and full commercialization by supporting activities that require significant outsourcing, such as regulatory strategy, intellectual property development, manufacturing optimization, pre-clinical product development, and clinical trials—though not all NIH institutes accept clinical trial proposals. The program permits substantial outsourcing to contract research organizations but requires the small business to maintain active oversight and management of all scientific, financial, and administrative aspects of the work, with justified budget allocations reflecting this role. CRP funding cannot cover FDA filing fees or include separate Technical and Business Assistance (TABA) funds. Eligible applicants must be small business concerns under 500 employees meeting SBA size standards, and proposals must align with the mission of participating NIH components. The solicitation explicitly excludes applications that propose clinical trials solely aligned with certain NIH institutes, including NHLBI, NIAID, NIDDK, and others listed, which do not accept such trials under this program. Applications are limited to Type 1 new submissions, and prior Phase II funding is mandatory for eligibility. Applicants are strongly encouraged to consult with NIH program staff before submitting to ensure alignment with the most appropriate funding mechanism, as the Phase IIB Strategic Breakthrough program (PA-27-101) may be better suited for some projects with matching fund requirements. The solicitation is active through August 5, 2026, under a total small business set-aside, and further details are available through the NIH SBIR/STTR portal.
Department of Health and Human Services

POSTED

2 months ago

DEADLINE

in 8 months
View Details
NAICS: 325412
Federal
Revlimid_BPA
Solicitation # 36C77026A0003
The Department of Veterans Affairs (VA), through Network Contracting Office 15, awarded a 12-month Blanket Purchase Agreement (BPA) to Bristol-Myers Squibb for the brand-name pharmaceutical REVLIMID® (lenalidomide) capsules, commencing February 2, 2026, and ending February 1, 2027. This BPA was established as a sole-source 8(a) set-aside under GSAM/R 538.7104-3 due to the unique and highly specialized nature of REVLIMID®, which is subject to the FDA-mandated Lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program. The sole source award reflects the clinical necessity of using the brand-name product for certain patients intolerant to generic alternatives and the restrictive distribution requirements that limit supply to REMS-certified pharmacies. The program ensures uninterrupted access to the medication across the VA’s Veterans Integrated Service Networks (VISNs), replacing an expiring McKesson contract. This BPA is situated under Bristol-Myers Squibb's Federal Supply Schedule (FSS) contract and does not include option periods, indicating an interim emergency acquisition to avoid treatment disruptions. The procurement is governed by compliance with REMS-certified dispensing, strict brand-name exclusivity, and FDA requirements, with a focus on patient safety and supply chain reliability. Key administrative contacts include contracting officers and specialists located at the VA contracting office in Leavenworth, KS, while delivery and acceptance occur at VA medical centers and REMS-certified pharmacies nationwide. Pricing details and specific contract values were not disclosed, but the award is based on a best-value trade-off emphasizing regulatory compliance, product uniqueness, and clinical imperatives rather than low cost. Inspection and acceptance rely primarily on adherence to REMS protocols and FDA specifications rather than physical inspection standards. Overall, the contract underscores a specialized federal procurement tailored to the unique pharmaceutical and clinical needs of the Veterans Health Administration.
Department Of Veterans Affairs

POSTED

6 months ago

DEADLINE

N/A
View Details